Newsletter Subscribe
Enter your email address below and subscribe to our newsletter
Pharma & Drugs
Share your love
Nicox releases topline data from phase 3 Denali trial of NCX 470 in open-angle glaucoma or ocular hypertension patients
(Image Credit: AdobeStock/Naypong Studio) Nicox has announced that the phase 3 Denali trial of NCX 470 0.1% met the primary endpoint of non-inferiority in lowering intraocular pressure (IOP) from baseline in open-angle glaucoma or ocular hypertension patients compared to the…
FDA extends target action date for two Regeneron regulatory submissions to Q4 of 2025
(Image Credit: AdobeStock/Ascannio The US Food and Drug Administration (FDA) has extended the target action dates for Regeneron Pharmaceuticals’ 2 EYLEA HD (aflibercept) Injection 8 mg regulatory submissions to the fourth quarter of 2025. The 2 regulatory submissions include a Chemistry, Manufacturing,…
VivaVision Biotech appoints Quan Dong Nguyen to its scientific advisory board
(Image credit: AdobeStock) VivaVision Biotech Co., Ltd., appointed Quan Dong Nguyen, MD, MSc, FAAO, FARVO, FASRS, to its scientific advisory board. Nguyen is a professor of ophthalmology at the Byers Eye Institute, Stanford University School of Medicine. He is also…
The emerging era of presbyopia-correcting eye drops: What’s next?
(Image Credit: AdobeStock/taffpixture) Since 2021, only 1 prescription eye drop for the correction of presbyopia, pilocarpine HCI ophthalmic solution 1.25% (Vuity; AbbVie), has been available, with additional options expected soon. In early 2025, a second eye drop, pilocarpine HCI ophthalmic…
UK MHRA approves phase 2a study for ANXV for diabetic retinopathy
(Image credit: AdobeStock/Janis Smits) UK Medicines and Healthcare products Regulatory Agency (MHRA) has approved the start of a clinical Proof of Concept phase 2a study with the drug candidate ANXV in the eye disease diabetic retinopathy (DR). Patients with newly…
FDA clears IND for Opus Genetics’ OPGx-BEST1 gene therapy for inherited retinal disease
(Image Credit: AdobeStock/Corona Borealis) The US Food and Drug Administration (FDA) has accepted Opus Genetics’ Investigational New Drug (IND) application for OPGx-BEST1, a gene therapy for the treatment of bestrophin-1 (BEST1)-related inherited retinal disease (IRD). Best disease, or vitelliform macular…
Study establishes reference data set for geographic atrophy lesion progression
(Image Credit: AdobeStock/tadamichi) The lesion characteristics of patients with geographic atrophy (GA) were found to affect the lesion growth rate, with fovea-sparing, multifocal, and bilateral lesions having the fastest growth rates in a study published in Translational Vision Science &…
RemeGen and Santen Enter into Exclusive Licensing Agreement for Ophthalmic Innovative Drug RC28-E in Greater China and Asian countries – PR Newswire
RemeGen and Santen Enter into Exclusive Licensing Agreement for Ophthalmic Innovative Drug RC28-E in Greater China and Asian countries PR Newswire Source: Author: | Date: 2025-08-18 07:00:00 Source: Author: | Date: 2025-08-18 07:00:00
FDA Green Lights Amneal's $201M Generic Eye Drug: Q3 2025 Launch Set for Pred Forte Alternative – Stock Titan
FDA Green Lights Amneal’s $201M Generic Eye Drug: Q3 2025 Launch Set for Pred Forte Alternative Stock Titan Source: Author: | Date: 2025-06-12 07:00:00 Source: Author: | Date: 2025-06-12 07:00:00
Peptide Eye Drops Offer Hope for Dry AMD
Researchers from the Natural Product Drug Development Center at the Korea Institute of Science and Technology (KIST), led by Dr. Moon-Hyeong Seo, have developed an innovative therapeutic agent for dry age-related macular degeneration (AMD) in the form of peptide-based eye…